Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli.
about
Three decades of beta-lactamase inhibitorsbeta-Lactamases in laboratory and clinical resistanceA functional classification scheme for beta-lactamases and its correlation with molecular structureThe structural bases of antibiotic resistance in the clinically derived mutant beta-lactamases TEM-30, TEM-32, and TEM-34New beta -lactamase inhibitory protein (BLIP-I) from Streptomyces exfoliatus SMF19 and its roles on the morphological differentiation.Ampicillin-sulbactam and amoxicillin-clavulanate susceptibility testing of Escherichia coli isolates with different beta-lactam resistance phenotypesACI-1 from Acidaminococcus fermentans: characterization of the first beta-lactamase in Anaerobic cocciInhibitor-resistant TEM beta-lactamases: phenotypic, genetic and biochemical characteristics.Discriminatory detection of inhibitor-resistant beta-lactamases in Escherichia coli by single-strand conformation polymorphism-PCR.Phenotypic study of resistance of beta-lactamase-inhibitor-resistant TEM enzymes which differ by naturally occurring variations and by site-directed substitution at Asp276.Selection and characterization of beta-lactam-beta-lactamase inactivator-resistant mutants following PCR mutagenesis of the TEM-1 beta-lactamase geneCeftazidime-resistant Klebsiella pneumoniae and Escherichia coli isolates producing TEM-10 and TEM-43 beta-lactamases from St. Louis, MissouriEffect of hyperproduction of TEM-1 beta-lactamase on in vitro susceptibility of Escherichia coli to beta-lactam antibiotics.Molecular characterization of TEM-59 (IRT-17), a novel inhibitor-resistant TEM-derived beta-lactamase in a clinical isolate of Klebsiella oxytocaOrigin and evolution of the AmpC beta-lactamases of Citrobacter freundii.A potent new mode of beta-lactamase inhibition revealed by the 1.7 A X-ray crystallographic structure of the TEM-1-BLIP complex.Beta-lactamase nomenclature.A secondary drug resistance mutation of TEM-1 beta-lactamase that suppresses misfolding and aggregation.Predicting evolutionary potential: in vitro evolution accurately reproduces natural evolution of the tem beta-lactamase.Molecular characterization of nine different types of mutants among 107 inhibitor-resistant TEM beta-lactamases from clinical isolates of Escherichia coliIncidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli.First characterization of inhibitor-resistant TEM (IRT) beta-lactamases in Klebsiella pneumoniae strainsExtended-spectrum and inhibitor-resistant TEM-type beta-lactamases: mutations, specificity, and three-dimensional structure.Molecular aspects of high-level resistance to sulbactam-cefoperazone in Klebsiella oxytoca clinical isolates.Properties of IRT-14 (TEM-45), a newly characterized mutant of TEM-type beta-lactamases.Construction and characterization of an OHIO-1 beta-lactamase bearing Met69Ile and Gly238Ser mutations.Characterization of a new TEM-derived beta-lactamase produced in a Serratia marcescens strainInhibitor-resistant TEM (IRT) beta-lactamases with different substitutions at position 244Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA-1 beta-lactamase conferring resistance to beta-lactamase inhibitors.A natural polymorphism in beta-lactamase is a global suppressor.Molecular survey of beta-lactamases conferring resistance to newer beta-lactams in Enterobacteriaceae isolates from Polish hospitals.Quantifying nonspecific TEM beta-lactamase (blaTEM) genes in a wastewater streamAmoxicillin-clavulanate therapy increases childhood nasal colonization by methicillin-susceptible Staphylococcus aureus strains producing high levels of penicillinase.Essential oils, a new horizon in combating bacterial antibiotic resistanceCurrent challenges in antimicrobial chemotherapy: focus on ß-lactamase inhibition.The intrinsic resistome of bacterial pathogens.Commercial Essential Oils as Potential Antimicrobials to Treat Skin Diseases.Selection of naturally occurring extended-spectrum TEM beta-lactamase variants by fluctuating beta-lactam pressure.Structural basis for the extended substrate spectrum of AmpC BER and structure-guided discovery of the inhibition activity of citrate against the class C β-lactamases AmpC BER and CMY-10.Properties of mutant SHV-5 beta-lactamases constructed by substitution of isoleucine or valine for methionine at position 69.
P2860
Q24646623-643AD89F-CBF6-4F84-AFEE-963FA1467D2EQ24669605-B4A3DABB-D347-4F08-9536-6901EF0B98B1Q24677460-E8799298-35DF-4339-BDD1-E58012EAD935Q27639159-A4B0F3BA-4E1D-433F-9097-970BBA644D90Q30854268-5E16C58F-19F1-48DD-928B-1830529CEC87Q33548223-5B695EA9-3427-48EC-9ED8-D983340BF342Q33594694-83F80185-2411-4C9C-B2BF-145364AF71FCQ33647947-389E2F30-DC93-4D1B-99A6-E5F4E3AAB269Q33692735-5805D53A-E05D-4BD3-A664-6D3EA03EBC5AQ33693187-477FDBF3-A63E-45A6-8A35-D782BAEAFFE4Q33693837-B5811FE4-DB36-4407-9E5B-EB2E810AD55DQ33694083-6385F238-11AC-4FF4-B038-D6CC804EDB65Q33750810-0E9F7057-C18D-44C1-BD86-23950B9BC92CQ33977130-D5141372-31B4-4037-B102-BF5D22F05AA5Q34107174-3CC139C1-3E0F-4832-911F-8C32CD8094A1Q34375789-198274CA-2362-478F-B52F-EB86D48ACBBFQ34510623-25454438-ED06-4336-A379-879D24FA6D36Q34594475-FDF28238-E091-4038-A188-78765366B700Q34614621-09C3AEEE-55D4-40CD-BA5F-E11B70F28B6AQ35111680-6F18539E-5A60-4AFF-952F-FCBD1BAF87FFQ35120245-8677B8EA-39CC-433A-821A-A7F0FDA10327Q35120452-D2DB74CD-6CAF-404A-911B-2EBDD07B78F4Q35120519-47021335-5782-4A44-AAD1-DFE3C47E6837Q35126478-ED13F880-4AEB-4500-89C4-B0F6D8BC1B11Q35132416-13CB8212-A8F3-4177-B9D4-0B01A051B699Q35138077-40F7DE22-4FCE-4628-85E9-EECA1B190A4FQ35138799-52ADA182-1BC5-4E5F-BED4-78A4CA392461Q35139062-B1E7A6EB-9727-4F1F-A2F4-FFB12224A6D3Q35820623-A9786FBB-80C8-4483-80A8-183F6B78F9B7Q36560876-91ED485B-182A-4FED-852E-E33C4E50AE4BQ36744818-71CEB6DA-5871-4D45-9A9C-7E460F4B9212Q37032925-41AB9BE6-4E2F-4895-A961-1AAE09DC3A4AQ37624545-B6C12CA7-36C3-4CB7-B72B-F015658B5A41Q37632354-F9866302-7936-4F20-BBC4-2283EEB306E2Q37731521-926EED42-77F2-43E8-B354-EEB30DD1A95FQ38103861-C5FF3FB4-3BD5-4F6A-B333-1A3F04557F24Q39331661-FE390825-0E24-46A3-98C7-05322676DC76Q39474681-DCC570D7-5C3E-4418-8572-910B88E89FB6Q39528655-2970332D-ED07-4AF3-9236-14A2B21EEEC1Q39558648-B1547E7F-0BB5-4220-BC7E-38D78A6289C5
P2860
Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Characterization of a new TEM- ...... l isolate of Escherichia coli.
@ast
Characterization of a new TEM- ...... l isolate of Escherichia coli.
@en
type
label
Characterization of a new TEM- ...... l isolate of Escherichia coli.
@ast
Characterization of a new TEM- ...... l isolate of Escherichia coli.
@en
prefLabel
Characterization of a new TEM- ...... l isolate of Escherichia coli.
@ast
Characterization of a new TEM- ...... l isolate of Escherichia coli.
@en
P2093
P2860
P356
P1476
Characterization of a new TEM- ...... al isolate of Escherichia coli
@en
P2093
P2860
P304
P356
10.1128/AAC.37.10.2059
P407
P50
P577
1993-10-01T00:00:00Z